Aytu Biopharma, Inc.
AYTU
$2.39
$0.0954.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.45M | 16.22M | 16.57M | 17.98M | 14.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.45M | 16.22M | 16.57M | 17.98M | 14.03M |
| Cost of Revenue | 5.65M | 5.44M | 4.59M | 5.34M | 3.66M |
| Gross Profit | 12.81M | 10.79M | 11.99M | 12.64M | 10.36M |
| SG&A Expenses | 9.30M | 9.72M | 10.78M | 11.09M | 10.18M |
| Depreciation & Amortization | 920.00K | 921.00K | 921.00K | 1.30M | 920.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.03M | 16.60M | 16.72M | 18.78M | 15.38M |
| Operating Income | 2.42M | -378.00K | -146.00K | -799.00K | -1.35M |
| Income Before Tax | 3.82M | 382.00K | 1.50M | -3.92M | -1.77M |
| Income Tax Expenses | -122.00K | -283.00K | 405.00K | 695.00K | 521.00K |
| Earnings from Continuing Operations | 3.94M | 665.00K | 1.09M | -4.62M | -2.29M |
| Earnings from Discontinued Operations | 54.00K | 123.00K | 381.00K | -- | -599.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.99M | 788.00K | 1.47M | -4.62M | -2.89M |
| EBIT | 2.42M | -378.00K | -146.00K | -799.00K | -1.35M |
| EBITDA | 3.74M | 961.00K | 1.28M | 1.15M | 180.00K |
| EPS Basic | 0.65 | 0.13 | 0.24 | -0.82 | -0.52 |
| Normalized Basic EPS | 0.39 | 0.17 | 0.24 | 0.00 | -0.17 |
| EPS Diluted | 0.21 | -0.26 | -0.16 | -0.82 | -0.52 |
| Normalized Diluted EPS | 0.29 | 0.13 | 0.16 | 0.00 | -0.17 |
| Average Basic Shares Outstanding | 6.13M | 6.13M | 6.07M | 5.62M | 5.53M |
| Average Diluted Shares Outstanding | 8.20M | 8.49M | 9.10M | 5.62M | 5.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |